Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment(1) that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of
elderly people, targeting potential market opportunities of USD 3-6 billion.
Leuven, BELGIUM - January 19, 2024 - 07.00 PM CET - In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (https://www.oxurion.com/) (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), announces the below information, following the issuance of 326,086,956 new ordinary shares on January 9, 2024, for a total amount of EUR 150,000, as the result of the conversion of 6 convertible bonds, and the issuance of 217,391,304 new ordinary shares on January 16, 2024, for a total amount of EUR 100,000, as the result of the conversion of 4 convertible bonds, both pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC
Following completion of capital increases through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 4,032,937,232 outstanding ordinary shares carrying voting rights (compared to 3,489,458,972 outstanding ordinary shares prior to the two aforementioned issuances). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:

   * Share capital (EUR)                                          83,556,161.32
   * Total number of securities with
     voting rights (all ordinary shares)                          4,032,937,232
   * Total number of ordinary shares (=
     denominator)                                                 4,032,937,232
   * Number of outstanding, granted rights
     to subscribe to securities carrying
     voting rights not yet issued
     (excluding any shares resulting (a)
     from the potential conversion of any
     convertibles bonds issued on December
     20, 2021 to the benefit of Kreos
     Capital VI (UK) Limited, Pontifax
     Medison Finance (Israel) L.P. and
     Pontifax Medison Finance (Cayman)
     L.P. or (b) from the exercise of any
     subscription rights issued by the
     Company to the benefits of employees,
     consultants or directors of the
     Company (as they are both currently
     significantly out-of-the-money):
   * 306 convertible bonds issued on March 14, 2023, April 20, 2023, May
     22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October
     20, 2023, October 24, 2023, November 15, 2023 and January 9, 2024,
     entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a
     total number of securities carrying voting rights (all ordinary shares) in
     accordance with the terms and conditions of these convertible bonds
     pursuant to the Subscription Agreement entered into between the Company
     and Atlas Special Opportunities, LLC on March 1, 2023, as amended on
     September 10, 2023 and December 22, 2023.
                                      END

About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com (http://www.oxurion.com).
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events, or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report. This press release does not constitute an offer or
invitation for the sale or purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as amended,
or in compliance with an exemption therefrom, and in accordance with any
applicable U.S. state securities laws.
For further information please contact:
+------------------------------------+-----------------------------------------+
|Oxurion NV |US | |Pascal Ghoson |Conway Communications | |Chief Executive Officer |Mary T. Conway | |pascal.ghoson@oxurion.com |mtconway@conwaycommsir.com | |(mailto:pascal.ghoson@oxurion.com) |(mailto:mtconway@conwaycommsir.com) | | | | +------------------------------------+-----------------------------------------+
--------------------------------------------------------------------------------
(1) Press release Oxurion, 02/03/2023 (https://ir.oxurion.com/news-
releases/news-release-details/oxurion-announces-subscription-agreement-atlas-
providing-company)
Â